Avidity Biosciences (NASDAQ: RNA) announced encouraging initial data from the phase I/II FORTITUDE study evaluating two doses of delpacibart braxlosiran (del-brax, or formerly AOC 1020) in facioscapulohumeral muscular dystrophy (FSHD), a rare genetic disease of the muscles.
Heron Therapeutics, Inc. (NASDAQ:HRTX – Get Free Report) saw a significant increase in short interest in the month of May. As of May 15th, there was short interest totalling 30,270,000 shares, an increase of 10.9% from the April 30th total of 27,290,000 shares. Based on an average daily volume of 2,410,000 shares, the short-interest ratio […]
Heron Therapeutics, Inc. (NASDAQ:HRTX – Get Free Report) was the target of a large growth in short interest during the month of May. As of May 15th, there was short interest totalling 30,270,000 shares, a growth of 10.9% from the April 30th total of 27,290,000 shares. Based on an average trading volume of 2,410,000 shares, […]
Heron Therapeutics, Inc. (NASDAQ:HRTX – Get Free Report) was the recipient of a significant increase in short interest in the month of May. As of May 15th, there was short interest totalling 30,270,000 shares, an increase of 10.9% from the April 30th total of 27,290,000 shares. Based on an average daily trading volume, of 2,410,000 […]